Recent Updates
Recently added Catalysts
QURE Negative Sentiment Score: 20/100

uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE

Key Takeaway: ClaimsFiler has announced to investors that the deadline for filing lead plaintiff applications in a class action lawsuit against uniQure N.V. is April 13, 2026. This lawsuit is due to allegations that uniQure failed to disclose crucial information related to its drug candidate AMT-130, which is now facing uncertain FDA approval. The company's stock plummeted over 49% after disclosing that data from Phase I/II studies may not support its Biologics License Application submission. The lawsuit is pending in the Southern District of New York.

Market Sentiment Analysis

CONCERNS & RISKS

  • UniQure is facing a class action lawsuit due to alleged failure to disclose material information.
  • The company's leading drug candidate AMT-130 is now uncertain for FDA approval.
  • The stock price dropped over 49% following negative news on AMT-130's BLA submission timeline.

Full Press Release Details

NEW ORLEANS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (“uniQure” or the “Company”), if they purchased or otherwise acquired the Company’s shares between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
uniQure investors should visit us at https://claimsfiler.com/cases/nasdaq-qure/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
uniQure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
During the Class Period, the Company represented to investors that there was a high likelihood that its leading drug candidate, AMT-130, would receive accelerated approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s planned Biologics License Application (“BLA”) submission in the first quarter of 2026. However, on November 3, 2025, the Company disclosed that “the FDA currently no longer agrees that the data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission” and as a result, “the timing of the BLA submission for AMT-130 is now unclear.”
On this news, the price of uniQure’s shares plummeted $33.40 per share, or more than 49%, from a close of $67.69 per share on October 31, 2025, to close at $34.29 per share on November 3, 2025.
The case is Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file a lead plaintiff application?

Investors must file lead plaintiff applications by April 13, 2026.

What was the class period for the uniQure lawsuit?

The class period for the lawsuit is from September 24, 2025, to October 31, 2025.

What triggered the lawsuit against uniQure N.V.?

The lawsuit was triggered by uniQure's executives failing to disclose crucial information.

What happened to uniQure's stock price on November 3, 2025?

uniQure's stock price fell over 49%, dropping from $67.69 to $34.29.

How can I access claims information at ClaimsFiler?

Investors can register for free at ClaimsFiler.com for access to claims information.

Last updated: Feb 12, 2026